Fate Therapeutics (FATE) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fate Therapeutics (FATE) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 10.8% versus a loss of 63.4%. Over five years, VYGR leads with a -50.0% price change compared with -98.3% for FATE. Fate Therapeutics is the larger company by market cap ($111.8 million vs $95.2 million), about 1.2 times the size, while Voyager Therapeutics is growing revenue faster (-49.5% vs -51.2%).
Voyager Therapeutics converts more of its revenue into profit, with a net margin of -296.5% versus -2051.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FATE | VYGR |
|---|---|---|
| Share price | $0.919 | $1.53 |
| Market cap | $111.82M | $95.21M |
| 1-day change | -9.01% | -4.97% |
| YTD return | -6.22% | -61.07% |
| 1-year return | -10.78% | -63.40% |
| 5-year return | -98.25% | -50.00% |
| EPS (TTM) | $-1.03 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.65M | $40.37M |
| Revenue growth (YoY) | -51.24% | -49.53% |
| Net income (latest FY) | $-136.31M | $-119.72M |
| Operating margin | -2222.45% | -326.56% |
| Net margin | -2051.08% | -296.53% |
| 52-week high | $3.23 | $5.48 |
| 52-week low | $0.90 | $1.48 |
| Distance from 52-week high | -71.55% | -72.08% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +522.42% | +829.41% |
| Average volume | 1.53M | 770.24K |
| Shares outstanding | 121.67M | 62.23M |
| Employees | 161 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FATE has outperformed VYGR by 52.6 percentage points over the past year.
- Voyager Therapeutics is more profitable, keeping -296.5 cents of every revenue dollar as net income versus -2051.1 cents for Fate Therapeutics.
About Fate Therapeutics
FATE stock →Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 161 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
FATE vs VYGR FAQ
Which is bigger, Fate Therapeutics or Voyager Therapeutics?
Fate Therapeutics (FATE) is larger, with a market capitalization of $111.82M compared with $95.21M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, FATE or VYGR?
FATE returned -10.78% over the past 12 months, compared with -63.40% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are Fate Therapeutics and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.